Key facts
- This page summarizes Adam Morgan's Form 4/A - Amendment filing for HERON THERAPEUTICS, INC. /DE/ (HRTX).
- 2 reported transactions and 1 derivative row are listed below.
- Accepted by SEC: 04 Feb 2025, 17:37.
Adam Morgan - 31 Jan 2025 Form 4/A - Amendment Insider Report for HERON THERAPEUTICS, INC. /DE/ (HRTX)
- Reporting relationship
- Director
- Issuer ticker
- HRTX
- Reported as of
- 31 Jan 2025
- Net transaction value
- $0
- SEC form
- 4/A - Amendment
- Accepted by SEC
- 04 Feb 2025, 17:37:16 UTC
- Original report date
- 03 Feb 2025
- Prior SEC filing
- 03 Feb 2025
- Next SEC filing
- 12 Aug 2025
- Source filing
- View source filing
- Reporting owner signature
- /s/Kathryn Lester Attorney-in-fact for Adam Morgan
Source evidence
Original filing metadata and source links for verification.
6 source fields
Reporting owner
1 detail
Key filing fact
Adam Morgan filed Form 4/A - Amendment for HERON THERAPEUTICS, INC. /DE/ (HRTX) on 04 Feb 2025.
Change
- Previous filing in this sequence was filed on 03 Feb 2025.
- Current net transaction value: $0.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4/A - Amendment disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
HRTX
transaction
Common Stock
Award
- Transaction value
- $0
- Shares
- +17,950
- Change %
- +35%
- Price
- $0.000000
- Shares after
- 69,777
- Date
- 31 Jan 2025
- Ownership
- Direct
- Footnotes
- F1
HRTX
holding
Common Stock
No transaction description listed
- Transaction value
- Shares
- Change %
- Price
- Shares after
- 6,986,744
- Date
- 31 Jan 2025
- Ownership
- By Velan Capital Master Fund LP
- Footnotes
- F2
Reported derivative securities
Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.
HRTX
transaction
Derivative
Stock Option (Right to Buy)
Award
- Transaction value
- $0
- Shares
- +35,900
- Change %
- Price
- $0.000000
- Shares after
- 35,900
- Date
- 31 Jan 2025
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
- 35,900
- Exercise price
- $1.70
- Footnotes
- F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
The shares were granted as restricted stock units which vest in full on January 31, 2026. Each restricted stock unit represents a contingent right to receive one share of common stock.
Footnote F2
Securities owned directly by Velan Capital Master Fund LP ("Velan Master"). Mr. Morgan, as a managing member of each of Velan Capital Holdings LLC, the general partner of Velan Master, and Velan Capital Management LLC, the general partner of the investment manager of Velan Master, may be deemed to beneficially own the securities owned directly by Velan Master. Mr. Morgan disclaims beneficial ownership of the securities reported herein except to the extent of his pecuniary interest therein, and this report shall not be deemed to be an admission that Mr. Morgan is the beneficial owner of such securities for purposes of Section 16 or for any other purpose.
Footnote F3
The stock options vest and become exercisable in 12 equal monthly installments beginning one month after the date of grant.